Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

STXS vs BSX vs ISRG vs MDT

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
STXS
Stereotaxis, Inc.

Medical - Instruments & Supplies

HealthcareAMEX • US
Market Cap$177M
5Y Perf.-54.0%
BSX
Boston Scientific Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$84.08B
5Y Perf.+48.9%
ISRG
Intuitive Surgical, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$161.07B
5Y Perf.+134.6%
MDT
Medtronic plc

Medical - Devices

HealthcareNYSE • IE
Market Cap$99.94B
5Y Perf.-20.9%

STXS vs BSX vs ISRG vs MDT — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
STXS logoSTXS
BSX logoBSX
ISRG logoISRG
MDT logoMDT
IndustryMedical - Instruments & SuppliesMedical - DevicesMedical - Instruments & SuppliesMedical - Devices
Market Cap$177M$84.08B$161.07B$99.94B
Revenue (TTM)$30M$20.07B$10.58B$35.48B
Net Income (TTM)$-24M$2.89B$2.98B$4.61B
Gross Margin53.1%69.0%66.3%61.9%
Operating Margin-80.1%19.8%30.5%17.9%
Forward P/E16.7x43.8x14.1x
Total Debt$6M$12.42B$303M$28.52B
Cash & Equiv.$12M$2.04B$3.37B$2.22B

STXS vs BSX vs ISRG vs MDTLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

STXS
BSX
ISRG
MDT
StockMay 20May 26Return
Stereotaxis, Inc. (STXS)10046.0-54.0%
Boston Scientific C… (BSX)100148.9+48.9%
Intuitive Surgical,… (ISRG)100234.6+134.6%
Medtronic plc (MDT)10079.1-20.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: STXS vs BSX vs ISRG vs MDT

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MDT leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and dividend income and shareholder returns. Intuitive Surgical, Inc. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. BSX also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
STXS
Stereotaxis, Inc.
The Secondary Option

STXS lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
BSX
Boston Scientific Corporation
The Defensive Pick

BSX is the clearest fit if your priority is sleep-well-at-night and defensive.

  • Lower volatility, beta 0.34, Low D/E 50.7%, current ratio 1.62x
  • Beta 0.34, current ratio 1.62x
  • Beta 0.34 vs STXS's 1.73, lower leverage
Best for: sleep-well-at-night and defensive
ISRG
Intuitive Surgical, Inc.
The Growth Play

ISRG is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.

  • Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
  • 5.5% 10Y total return vs BSX's 155.5%
  • PEG 2.01 vs MDT's 36.00
  • 20.5% revenue growth vs STXS's 0.5%
Best for: growth exposure and long-term compounding
MDT
Medtronic plc
The Income Pick

MDT carries the broadest edge in this set and is the clearest fit for income & stability.

  • Dividend streak 36 yrs, beta 0.47, yield 3.6%
  • Lower P/E (14.1x vs 16.7x)
  • 3.6% yield; 36-year raise streak; the other 3 pay no meaningful dividend
  • -2.8% vs BSX's -46.0%
Best for: income & stability
See the full category breakdown
CategoryWinnerWhy
GrowthISRG logoISRG20.5% revenue growth vs STXS's 0.5%
ValueMDT logoMDTLower P/E (14.1x vs 16.7x)
Quality / MarginsISRG logoISRG28.2% margin vs STXS's -78.6%
Stability / SafetyBSX logoBSXBeta 0.34 vs STXS's 1.73, lower leverage
DividendsMDT logoMDT3.6% yield; 36-year raise streak; the other 3 pay no meaningful dividend
Momentum (1Y)MDT logoMDT-2.8% vs BSX's -46.0%
Efficiency (ROA)MDT logoMDT175.8% ROA vs STXS's -52.7%, ROIC 6.0% vs -289.6%

STXS vs BSX vs ISRG vs MDT — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

STXSStereotaxis, Inc.
FY 2024
Disposables, service and accessories
67.9%$18M
Systems
32.1%$9M
BSXBoston Scientific Corporation
FY 2025
Cardiovascular
66.0%$13.3B
MedSurg
34.0%$6.8B
ISRGIntuitive Surgical, Inc.
FY 2025
Instruments and Accessories
59.8%$6.0B
Systems
24.6%$2.5B
Services
15.6%$1.6B
MDTMedtronic plc
FY 2025
Cardiac and Vascular Group
37.3%$12.5B
Neuroscience Group
29.4%$9.8B
Medical Surgical
25.1%$8.4B
Diabetes Group
8.2%$2.8B

STXS vs BSX vs ISRG vs MDT — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLISRGLAGGINGBSX

Income & Cash Flow (Last 12 Months)

ISRG leads this category, winning 5 of 6 comparable metrics.

MDT is the larger business by revenue, generating $35.5B annually — 1179.9x STXS's $30M. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to STXS's -78.6%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricSTXS logoSTXSStereotaxis, Inc.BSX logoBSXBoston Scientific…ISRG logoISRGIntuitive Surgica…MDT logoMDTMedtronic plc
RevenueTrailing 12 months$30M$20.1B$10.6B$35.5B
EBITDAEarnings before interest/tax-$23M$4.7B$3.8B$9.4B
Net IncomeAfter-tax profit-$24M$2.9B$3.0B$4.6B
Free Cash FlowCash after capex-$8M$3.6B$2.8B$5.4B
Gross MarginGross profit ÷ Revenue+53.1%+69.0%+66.3%+61.9%
Operating MarginEBIT ÷ Revenue-80.1%+19.8%+30.5%+17.9%
Net MarginNet income ÷ Revenue-78.6%+14.4%+28.2%+13.0%
FCF MarginFCF ÷ Revenue-28.2%+18.1%+26.8%+15.2%
Rev. Growth (YoY)Latest quarter vs prior year-18.8%+15.9%+23.0%+8.8%
EPS Growth (YoY)Latest quarter vs prior year+3.0%+18.5%+18.8%-11.9%
ISRG leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

MDT leads this category, winning 5 of 7 comparable metrics.

At 21.6x trailing earnings, MDT trades at a 63% valuation discount to ISRG's 57.6x P/E. Adjusting for growth (PEG ratio), ISRG offers better value at 2.65x vs MDT's 36.00x — a lower PEG means you pay less per unit of expected earnings growth.

MetricSTXS logoSTXSStereotaxis, Inc.BSX logoBSXBoston Scientific…ISRG logoISRGIntuitive Surgica…MDT logoMDTMedtronic plc
Market CapShares × price$177M$84.1B$161.1B$99.9B
Enterprise ValueMkt cap + debt − cash$171M$94.5B$158.0B$126.2B
Trailing P/EPrice ÷ TTM EPS-6.33x29.16x57.62x21.60x
Forward P/EPrice ÷ next-FY EPS est.16.75x43.84x14.13x
PEG RatioP/E ÷ EPS growth rate2.65x36.00x
EV / EBITDAEnterprise value multiple25.30x43.62x14.32x
Price / SalesMarket cap ÷ Revenue6.59x4.19x16.00x2.98x
Price / BookPrice ÷ Book value/share14.16x3.46x9.17x2.08x
Price / FCFMarket cap ÷ FCF22.99x64.67x19.28x
MDT leads this category, winning 5 of 7 comparable metrics.

Profitability & Efficiency

ISRG leads this category, winning 5 of 9 comparable metrics.

ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-2 for STXS. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to MDT's 0.59x. On the Piotroski fundamental quality scale (0–9), BSX scores 7/9 vs STXS's 2/9, reflecting strong financial health.

MetricSTXS logoSTXSStereotaxis, Inc.BSX logoBSXBoston Scientific…ISRG logoISRGIntuitive Surgica…MDT logoMDTMedtronic plc
ROE (TTM)Return on equity-2.5%+12.4%+16.9%+9.4%
ROA (TTM)Return on assets-52.7%+6.9%+14.8%+175.8%
ROICReturn on invested capital-2.9%+8.8%+15.0%+6.0%
ROCEReturn on capital employed-92.0%+11.1%+16.5%+7.5%
Piotroski ScoreFundamental quality 0–92766
Debt / EquityFinancial leverage0.53x0.51x0.02x0.59x
Net DebtTotal debt minus cash-$6M$10.4B-$3.1B$26.3B
Cash & Equiv.Liquid assets$12M$2.0B$3.4B$2.2B
Total DebtShort + long-term debt$6M$12.4B$303M$28.5B
Interest CoverageEBIT ÷ Interest expense11.03x9.08x
ISRG leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

ISRG leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in ISRG five years ago would be worth $15,873 today (with dividends reinvested), compared to $2,836 for STXS. Over the past 12 months, MDT leads with a -2.8% total return vs BSX's -46.0%. The 3-year compound annual growth rate (CAGR) favors ISRG at 14.4% vs MDT's -1.4% — a key indicator of consistent wealth creation.

MetricSTXS logoSTXSStereotaxis, Inc.BSX logoBSXBoston Scientific…ISRG logoISRGIntuitive Surgica…MDT logoMDTMedtronic plc
YTD ReturnYear-to-date-18.1%-40.3%-19.3%-18.1%
1-Year ReturnPast 12 months-9.1%-46.0%-15.4%-2.8%
3-Year ReturnCumulative with dividends+8.0%+6.5%+49.6%-4.2%
5-Year ReturnCumulative with dividends-71.6%+31.2%+58.7%-27.7%
10-Year ReturnCumulative with dividends+25.0%+155.5%+554.2%+26.5%
CAGR (3Y)Annualised 3-year return+2.6%+2.1%+14.4%-1.4%
ISRG leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — BSX and ISRG each lead in 1 of 2 comparable metrics.

BSX is the less volatile stock with a 0.34 beta — it tends to amplify market swings less than STXS's 1.73 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ISRG currently trades 75.1% from its 52-week high vs BSX's 51.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSTXS logoSTXSStereotaxis, Inc.BSX logoBSXBoston Scientific…ISRG logoISRGIntuitive Surgica…MDT logoMDTMedtronic plc
Beta (5Y)Sensitivity to S&P 5001.73x0.34x1.02x0.47x
52-Week HighHighest price in past year$3.59$109.50$603.88$106.33
52-Week LowLowest price in past year$1.74$54.98$427.84$77.16
% of 52W HighCurrent price vs 52-week peak+52.9%+51.7%+75.1%+73.3%
RSI (14)Momentum oscillator 0–10049.733.242.427.3
Avg Volume (50D)Average daily shares traded409K15.5M1.8M7.8M
Evenly matched — BSX and ISRG each lead in 1 of 2 comparable metrics.

Analyst Outlook

MDT leads this category, winning 1 of 1 comparable metric.

Analyst consensus: STXS as "Buy", BSX as "Buy", ISRG as "Buy", MDT as "Buy". Consensus price targets imply 110.5% upside for STXS (target: $4) vs 37.3% for ISRG (target: $623). MDT is the only dividend payer here at 3.57% yield — a key consideration for income-focused portfolios.

MetricSTXS logoSTXSStereotaxis, Inc.BSX logoBSXBoston Scientific…ISRG logoISRGIntuitive Surgica…MDT logoMDTMedtronic plc
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$4.00$91.33$622.60$109.50
# AnalystsCovering analysts10435549
Dividend YieldAnnual dividend ÷ price+3.6%
Dividend StreakConsecutive years of raises036
Dividend / ShareAnnual DPS$2.78
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+1.4%+3.2%
MDT leads this category, winning 1 of 1 comparable metric.
Key Takeaway

ISRG leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MDT leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.

Best OverallIntuitive Surgical, Inc. (ISRG)Leads 3 of 6 categories
Loading custom metrics...

STXS vs BSX vs ISRG vs MDT: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is STXS or BSX or ISRG or MDT a better buy right now?

For growth investors, Intuitive Surgical, Inc.

(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus 0. 5% for Stereotaxis, Inc. (STXS). Medtronic plc (MDT) offers the better valuation at 21. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Stereotaxis, Inc. (STXS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — STXS or BSX or ISRG or MDT?

On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.

6x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, Medtronic plc is actually cheaper at 14. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Intuitive Surgical, Inc. wins at 2. 01x versus Medtronic plc's 36. 00x.

03

Which is the better long-term investment — STXS or BSX or ISRG or MDT?

Over the past 5 years, Intuitive Surgical, Inc.

(ISRG) delivered a total return of +58. 7%, compared to -71. 6% for Stereotaxis, Inc. (STXS). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus STXS's +25. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — STXS or BSX or ISRG or MDT?

By beta (market sensitivity over 5 years), Boston Scientific Corporation (BSX) is the lower-risk stock at 0.

34β versus Stereotaxis, Inc. 's 1. 73β — meaning STXS is approximately 402% more volatile than BSX relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 59% for Medtronic plc — giving it more financial flexibility in a downturn.

05

Which is growing faster — STXS or BSX or ISRG or MDT?

By revenue growth (latest reported year), Intuitive Surgical, Inc.

(ISRG) is pulling ahead at 20. 5% versus 0. 5% for Stereotaxis, Inc. (STXS). On earnings-per-share growth, the picture is similar: Boston Scientific Corporation grew EPS 55. 2% year-over-year, compared to -11. 1% for Stereotaxis, Inc.. Over a 3-year CAGR, ISRG leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — STXS or BSX or ISRG or MDT?

Intuitive Surgical, Inc.

(ISRG) is the more profitable company, earning 28. 4% net margin versus -89. 3% for Stereotaxis, Inc. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -91. 9% for STXS. At the gross margin level — before operating expenses — BSX leads at 69. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is STXS or BSX or ISRG or MDT more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Intuitive Surgical, Inc. (ISRG) is the more undervalued stock at a PEG of 2. 01x versus Medtronic plc's 36. 00x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Medtronic plc (MDT) trades at 14. 1x forward P/E versus 43. 8x for Intuitive Surgical, Inc. — 29. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for STXS: 110. 5% to $4. 00.

08

Which pays a better dividend — STXS or BSX or ISRG or MDT?

In this comparison, MDT (3.

6% yield) pays a dividend. STXS, BSX, ISRG do not pay a meaningful dividend and should not be held primarily for income.

09

Is STXS or BSX or ISRG or MDT better for a retirement portfolio?

For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

47), 3. 6% yield). Stereotaxis, Inc. (STXS) carries a higher beta of 1. 73 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDT: +26. 5%, STXS: +25. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between STXS and BSX and ISRG and MDT?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: STXS is a small-cap quality compounder stock; BSX is a mid-cap high-growth stock; ISRG is a mid-cap high-growth stock; MDT is a mid-cap income-oriented stock. MDT pays a dividend while STXS, BSX, ISRG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

STXS

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 31%
Run This Screen
Stocks Like

BSX

High-Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Net Margin > 8%
Run This Screen
Stocks Like

ISRG

High-Growth Quality Leader

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 11%
  • Net Margin > 16%
Run This Screen
Stocks Like

MDT

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform STXS and BSX and ISRG and MDT on the metrics below

Revenue Growth>
%
(STXS: -18.8% · BSX: 15.9%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.